Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cybin, Fibrogen, Jazz, OS Therapies, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Absci, Almirall, Coherus, Cormedix, Intas, Keros, Melinta, Novo Nordisk, Prothena.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Assembly, Braintree, Eledon, Eli Lilly, OS, Palisade, Sellas, Spinogenix.
Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in July, down from $7.38 billion in June.This year’s total falls short of $74.03 billion in the first seven months of 2024 and more than $80 billion in 2020 and 2021. However, 2025 is on track to outperform post-pandemic lows of 2022 and 2023, when the seven-month totals reached $33.14 billion and $36.47 billion, respectively.
RSS
